Cetrorelix

CHEMBL1200490 Phase 4 Approuvé Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1431.0 g/mol
LogP
1.9
Phase
4

A synthetic decapeptide antagonist of gonadotropin-releasing hormone (GnRH) that rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), preventing premature ovulation during controlled ovarian stimulation for assisted reproduction. Unlike GnRH agonists, it does not cause an initial hormonal flare. It is administered by subcutaneous injection during in vitro fertilization cycles.

Masse moléculaire

1431,0000 g/mol

LogP

1,90

TPSA

498,00 Ų

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Mécanisme d'action

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

InChI

InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1

Molecular Formula

C70H92ClN17O14

HBD / HBA

16 / 16

Liaisons Rotatives

38

Atomes Lourds

102

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A synthetic decapeptide antagonist of gonadotropin-releasing hormone (GnRH) that rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), preventing premature ovulation during controlled ovarian stimulation for assisted reproduction. Unlike GnRH agonists, it does not cause an initial hormonal flare. It is administered by subcutaneous injection during in vitro fertilization cycles.

Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.

Yes, Cetrorelix is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200490. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 25074887. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.